OncoMatch/Clinical Trials/NCT06320301
Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC)
Is NCT06320301 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Adebrelimab + GEMOX + TKI for biliary tract cancer.
Treatment: Adebrelimab + GEMOX + TKI — Patients with advanced biliary tract malignant tumors who had not received systematic treatment before and could not be cured were selected as the subjects of the study. The primary endpoint of the study was investigator-assessed 6-month progression-free survival (6-month PFS%) based on the RECIST v1.1 criteria, and 43 subjects were planned to be enrolled. Patients eligible for enrollment will receive Adebrelimab and a tyrosine kinase inhibitor (TKI) in combination with gemcitabine and oxaliplatin (GEMOX).
Check if I qualifyExtracted eligibility criteria
Cancer type
Cholangiocarcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: systemic therapy
Lab requirements
Blood counts
Hemoglobin ≥ 90 G/L; Neutrophil count ≥ 1.5 × 10^9/L; Platelet count ≥ 50 × 10^9/L
Kidney function
Creatinine ≤ 1.5x ULN or Cr clearance > 50 mL/min
Liver function
ALT and AST ≤ 2.5x ULN; total bilirubin ≤ 1.5x ULN
Cardiac function
LVEF ≥ 60%
The functions of main organs are basically normal...see protocol for details
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify